LQDA News and Press, Liquidia Technologies Inc.

2024-06-24 17:15:02 ET Oppenheimer analyst issues PERFORM recommendation for LQDA on June 24, 2024 04:14PM ET. LQDA was trading at $12.6 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy recommendat...

Liquidia to feature two live posters sessions and five encore presentations covering its investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension MORRISVILLE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Liqui...

2024-06-13 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Liquidia Corporation (NASDAQ: LQDA) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 12.51% on the day to $14.48. Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various produ...

On May 31, Judge Andrews denied United Therapeutics’ motion for a preliminary injunction to block the launch of YUTREPIA in the PH-ILD indication Ruling reinforces the clear path for FDA to issue final decision on amended NDA for YUTREPIA to treat both PAH and PH-ILD MORRISVILLE,...

2024-06-02 10:27:52 ET Summary United Therapeutics is a biotech company with a strong earnings growth and a lead product that contributes over 50% of its revenues. The company has been successful in preventing a competitive product from entering the market, but its options to cont...

2024-05-31 16:28:15 ET More on Liquidia Liquidia Corp.: A Rich Catalyst Path Lies Ahead For Value Unlocking Liquidia Corporation (LQDA) Q1 2024 Earnings Call Transcript Liquidia Corporation (LQDA) Q4 2023 Earnings Call Transcript Liquidia  Q1 2024 Earnin...

MORRISVILLE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Michael Kaseta, chief operating officer and chief financial officer, will provide an update on the company's business during a fireside chat at the 2024 Jefferies Global Healthca...

2024-05-22 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-17 10:17:19 ET Summary Liquidia's stock price has experienced an unjustified selloff, creating a buying opportunity. Potential catalysts include FDA approval of Yutrepia, legal wins on the 327 patent, and positive data readouts on PH-ILD studies. Sales data on Tyvaso a...